Ovid Therapeutics is led by Dr. Jeremy Levin, who serves as the Chairman and Chief Executive Officer of the public biopharmaceutical company. Bringing extensive leadership experience across the global life sciences sector, he previously served as the president and CEO of Teva Pharmaceutical Industries and held senior executive roles on the leadership committee of Bristol-Myers Squibb, where he engineered major strategic alliance initiatives. Under his direction, Ovid focuses heavily on developing innovative targeted medicines designed to treat rare epilepsies and specialized seizure-related neurological disorders.